Stock listing

Frankfurt:8CC Cocrystal Pharma, Inc. Aktie

German listing (Frankfurt) of Cocrystal Pharma, Inc. · home listing NASDAQ:COCP

Follow Cocrystal Pharma, Inc. into a list and get an email when it puts out news.

Share price · FWB:8CC

€0.85 EUR -0.02 (-2.3%)

Close on Nov 20, 2026

Past year +4.4% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€0.85 – €0.85 EURNov 20, 2026
Market cap
€16.37M EURAt the close on Nov 20, 2026 · price × 19.26M shares outstanding
52-week range
€0.686 – €1.30 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€7 EURMedian day 0 shares · 55 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
Cocrystal Pharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:COCP · Home$0.95 USD-0.027 (-2.8%)42,947$0.95$0.968$0.91$0.977Close on Nov 20, 2026
Frankfurt:8CC€0.85 EUR-0.02 (-2.3%)—€0.85€0.85€0.85€0.87Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:8CC · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€0.869+0.006+0.7%€0.869€0.869€0.8690
€0.863-0.058-6.3%€0.863€0.863€0.8630
€0.921-0.04-4.2%€0.921€0.921€0.921253
€0.961+0.101+11.7%€0.92€0.964€0.9160
€0.86+0.028+3.4%€0.86€0.86€0.860
€0.832-0.03-3.5%€0.832€0.832€0.8320
€0.862+0.005+0.6%€0.862€0.862€0.8620
€0.857+0.023+2.8%€0.857€0.857€0.8570
€0.834+0.009+1.1%€0.834€0.834€0.8340
€0.825+0.033+4.2%€0.825€0.825€0.8250
€0.792-0.01-1.2%€0.792€0.792€0.7920
€0.802-0.016-2.0%€0.802€0.802€0.8020
€0.818+0.005+0.6%€0.818€0.818€0.8180
€0.813-0.072-8.1%€0.813€0.813€0.8130
€0.885-0.033-3.6%€0.885€0.885€0.8850
€0.918+0.015+1.7%€0.892€0.92€0.8850
€0.903-0.034-3.6%€0.903€0.903€0.9030
€0.937+0.014+1.5%€0.937€0.937€0.9370
€0.923+0.004+0.4%€0.924€0.926€0.923187
€0.919+0.001+0.1%€0.919€0.919€0.9190
€0.918+0.007+0.8%€0.918€0.918€0.9180
€0.911-0.04-4.2%€0.911€0.911€0.9110
€0.951-0.011-1.1%€0.951€0.951€0.9510
€0.962-0.024-2.4%€0.962€0.962€0.9620
€0.986+0.003+0.3%€0.986€0.986€0.9860
€0.983-0.007-0.7%€0.983€0.983€0.9830
€0.99+0.034+3.6%€0.99€0.99€0.990
€0.956-0.069-6.7%€0.956€0.956€0.9560
€1.025+0.04+4.1%€1.025€1.025€1.0250
€0.985+0.005+0.5%€0.985€0.985€0.9850
€0.98-0.025-2.5%€0.98€0.98€0.980
€1.005-0.002-0.2%€1.005€1.005€1.0050
€1.007+0.005+0.5%€1.007€1.007€1.0070
€1.002-0.011-1.1%€1.002€1.002€1.0020
€1.013+0.048+5.0%€1.013€1.013€1.0130
€0.965-0.001-0.1%€0.965€0.965€0.9650
€0.966+0.003+0.3%€0.966€0.966€0.9660
€0.963-0.013-1.3%€0.963€0.963€0.9630
€0.976-0.054-5.2%€0.976€0.976€0.9760
€1.03-0.005-0.5%€1.03€1.03€1.030
€1.035-0.001-0.1%€1.035€1.035€1.0350
€1.036+0.047+4.8%€1.036€1.036€1.0360
€0.989+0.054+5.8%€0.989€0.989€0.9890
€0.935-0.004-0.4%€0.935€0.935€0.9350
€0.939-0.003-0.3%€0.939€0.939€0.9390
€0.942-0.026-2.7%€0.942€0.942€0.9420
€0.968+0.034+3.6%€0.968€0.968€0.9680
€0.934-0.033-3.4%€0.934€0.934€0.9340
€0.967+0.058+6.4%€0.967€0.967€0.9670
€0.909-0.036-3.8%€0.909€0.909€0.9090
€0.945+0.017+1.8%€0.945€0.945€0.9450
€0.928+0.002+0.2%€0.928€0.928€0.9280
€0.9260.000.0%€0.926€0.926€0.9260
€0.926-0.019-2.0%€0.926€0.926€0.9260
€0.945-0.025-2.6%€0.945€0.945€0.9450
€0.97+0.022+2.3%€0.97€0.97€0.970
€0.948+0.049+5.5%€0.948€0.948€0.9480

Splits

1 split · FWB:8CC · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
Ticker
Frankfurt:8CC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All Cocrystal Pharma, Inc. news

Cocrystal Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
15 in the last 12 months · 153 in all · newest Nov 15, 2026 · oldest 2019
Decks
29 decks · latest Apr 30, 2026

Where Cocrystal Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:COCP · Home listingNASDAQUnited StatesUSD
Tradegate:8CCTradegateGermanyEUR
Lang & Schwarz:A3DWYXLang & SchwarzGermanyEUR
LS Exchange:A3DWYXLS ExchangeGermanyEUR
gettex:8CCgettexGermanyEUR
BOATS:COCPBOATSUnited StatesUSD
Dusseldorf:8CCDusseldorfGermanyEUR
Frankfurt:8CC · This pageFrankfurtGermanyEUR
Munich:8CCMunichGermanyEUR
Stuttgart:8CCStuttgartGermanyEUR

Valuation

EV/sales 33.8× against a median of 4.9×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$14.69M USD
P/E
Loss
EV/sales
33.8×
EV/EBITDA
Negative EBITDA
Price/book
6.8×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.5×
Beta vs S&P 500
1.21

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cocrystal Pharma, Inc. · NASDAQ:COCPUS$18.30MUS$14.69Mn/a33.8×n/a6.8×n/a0.5×1.21
TransCode Therapeutics, Inc. · NASDAQ:RNAZUS$20.07MUS$15.44Mn/an/an/a0.6×n/a0.0×1.03
Adicet Bio, Inc. · NASDAQ:ACETUS$20.03MUS$5.02Mn/an/an/a0.2×n/a0.1×2.02
IGC Pharma, Inc. · AMEX:IGCUS$19.60MUS$19.19Mn/an/an/a3.0×n/a0.0×1.09
Provectus Biopharmaceuticals, Inc. · OTC:PVCTUS$19.12MUS$18.94Mn/an/an/an/an/an/a-0.21
LeonaBio, Inc. · NASDAQ:LONAUS$19.03M−US$12.82Mn/an/an/a1.2×n/a0.0×1.04
Syntara Limited · ASX:SNTUS$18.20MUS$9.23Mn/a2.0×n/a1.7×−129.8%0.0×n/a
Marker Therapeutics, Inc. · NASDAQ:MRKRUS$18.17MUS$9.13Mn/a4.9×n/a1.7×−461.1%0.0×1.49
Resverlogix Corp. · TSX:RVXUS$18.01MUS$95.55Mn/an/an/an/an/an/a0.26
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.76MUS$15.67Mn/an/an/a13.4×n/a1.1×n/a
Median of the othersUS$18.62MUS$13.91M4.9×1.7×−178.5%0.0×1.04

Forecasts

2 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
8.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.72 · 2 analysts
Revenue, year to Dec 2026
110M · 3 analysts

Team and board

Officers

OfficerRole
James SapirsteinChief Executive Officer
James J. MartinChief Financial Officer
Sam LeePresident and Chief Scientific Officer
Roger KornbergChairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board

Board

DirectorRole
Roger KornbergChairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
Steve RubinVice Chairman
Carol BrosgartDirector
Fred HassanDirector
Phillip FrostDirector
Richard C. PfennigerDirector

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026+3.0%
Q2 2026Aug 13, 2026 · Before open−1.8%
Q1 2026May 15, 2026 · Before open−4.8%
Q3 2025Nov 14, 2025 · Before open0.0%
Q2 2025Aug 14, 2025 · Before open0.0%
Q1 2025May 15, 2025 · Before open−1.4%
Q4 2024Mar 26, 2025 · Before open+1.4%
Q3 2024Nov 13, 2024 · Before open+0.6%
Q2 2024Aug 14, 2024 · Before open−10.5%
Q1 2024May 13, 2024 · Before open0.0%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 28, 2024 · Before open−6.7%
Q3 2023Nov 13, 2023 · Before open−1.1%
Q2 2023Aug 14, 2023 · Before open+4.2%
Q1 2023May 15, 2023 · Before open−5.3%
Q4 2022Mar 29, 2023 · Before open+1.7%
Q3 2022Nov 14, 2022 · Before open−1.0%
Q2 2022Aug 15, 2022 · Before open+4.3%
Q1 2022May 11, 2022 · Before open−5.0%
Q4 2021Mar 23, 2022 · After close+1.7%
Quarter to Sep 30, 2021Nov 15, 2021 · Before open0.0%

Open Events

Decks

DeckKindSlidesDate
2026 International Society For Antiviral Research (ICAR 2026)Conference17 slidesApr 30, 2026
Investor Presentation (April 2026)Investor deck29 slidesApril 2026
2025 International Calicivirus ConferenceConference25 slidesSep 11, 2025
2025 Military Health System Research SymposiumConference21 slidesAug 5, 2025
Life Science Innovation Northwest 2025Conference12 slidesApril 2025
Investor Presentation (January 2025)Investor deck27 slidesJan 13, 2025
Investor Presentation (January 2024)Investor deck22 slidesJan 8, 2024
Investor Presentation (December 2023)Investor deck31 slidesDec 4, 2023
World Vaccine Congress West Coast 2023Conference18 slidesNov 29, 2023
7th ISIRV-AVG Conference 2023Conference18 slidesMay 4, 2023
All 29 decks
DeckKindSlidesDate
Investor Presentation (January 2023)Investor deck29 slidesJan 9, 2023
2022 World Antiviral CongressConference23 slidesDec 1, 2022
Investor Presentation (October 2022)Investor deck32 slidesOct 26, 2022
Investor Presentation (September 2021)Investor deck31 slidesSep 14, 2021
Investor Presentation (July 2021)Investor deck34 slidesJul 12, 2021
Investor Presentation (March 2021)Investor deck33 slidesMar 9, 2021
reImagine HEALTH Intervention and Prevention Symposium (January 2021)Conference28 slidesJan 21, 2021
Investor Presentation (January 2021)Investor deck33 slidesJan 11, 2021
Investor Presentation (May 2020)Investor deck32 slidesMay 11, 2020
Investor Presentation (March 2020)Investor deck33 slidesMar 4, 2020
Investor Presentation (February 2020)Investor deck32 slidesFeb 18, 2020
Investor Presentation (October 2019)Investor deck32 slidesOct 4, 2019
Investor Presentation (June 2019)Investor deck30 slidesJun 4, 2019
Investor Presentation (January 2019)Investor deck30 slidesJan 4, 2019
ISIRV AVG Conference (November 2018)Conference24 slidesNov 13, 2018
Investor Presentation (June 2018)Investor deck48 slidesJun 4, 2018
Investor Presentation (April 2018)Investor deck48 slidesApr 9, 2018
Investor Presentation (January 2018)Investor deck31 slidesJan 8, 2018
Investor Presentation (January 2017)Investor deck18 slidesJan 9, 2017

Open Decks

Financings

RaiseDate
Private placement of common stock
Closed: US$5M raised · US$0.9134 a share
Buyers: OPKO (5,474,053 shares of common stock for $5.0 million)
Aug 3, 2026
Private placement of units of common stock and unregistered warrants
Closed: US$1.03M raised · US$1.39 a unit · Warrants at US$1.24 for 27 months
Buyers: Phillip Frost, M.D.; Fred Hassan; Richard Pfenniger; James Martin
Insiders: All four investors are insiders: directors Phillip Frost, Fred Hassan and Richard Pfenniger, and co-CEO and CFO James Martin
Use of proceeds: Support clinical development programs, working capital and general corporate purposes
Oct 30, 2025
Registered direct offering of shares of common stock with unregistered warrants
Closed: US$4.7M raised · US$1.7 a share · Warrants at US$1.5 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Working capital and general corporate purposes
Sep 15, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue00005.43M2.01M6.56M000
Cost of revenue5.05M12.5M15.2M12.4M8.79M6.03M4.00M50.0K101.0K201.0K
Gross profit-5.05M-12.5M-15.2M-12.4M-8.79M-4.02M2.56M-50.0K-101.0K-201.0K
Research and development5.05M12.5M15.2M12.4M8.79M6.03M4.00M4.67M5.82M101.7M
Selling, general and administrative3.96M5.34M5.99M5.75M5.43M5.57M4.86M4.35M2.44M4.14M
Operating income-9.02M-17.9M-18.6M-38.8M-14.2M-9.59M-48.4M-62.9M-8.26M-105.8M
Depreciation and amortization72.0K126.0K189.0K185.0K190.0K157.0K98.0K50.0K101.0K201.0K
EBITDA-8.95M-17.8M-18.4M-38.6M-14.0M-9.43M-48.3M-62.9M-8.16M-105.6M
Interest expense-134.0K-537.0K-640.0K2.00K4.00K8.00K19.0K58.0K00
Income before tax-8.83M-18.6M-18.0M-38.8M-14.2M-9.65M-48.2M-62.6M-7.49M-104.3M
Income tax-17.5M-18.00K4.00K8.00K19.0K-13.6M-6.88M-29.4M
Net income-8.83M-17.5M-18.0M-38.8M-14.2M-9.65M-48.2M-49.0M-613.0K-74.9M
Earnings per share, basic-0.78-1.72-1.87-4.77-0.16-0.17-1.51-1.75-0.03-3.18
Earnings per share, diluted-0.78-1.72-1.87-4.77-0.16-0.17-1.51-1.75-0.03-3.30

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents7.03M9.86M26.4M37.1M58.7M33.0M7.42M2.72M748.0K3.60M
Short-term investments29.0K
Receivables706.0K1.22M890.0K716.0K0556.0K644.0K1.00K21.0K
Inventory75.0K50.0K50.0K29.0K
Current assets8.13M11.6M29.1M40.2M59.3M34.0M8.28M2.94M2.18M5.47M
Property, plant and equipment93.0K153.0K271.0K342.0K453.0K591.0K431.0K384.0K119.0K280.0K
Goodwill019.1M19.1M19.1M65.2M65.2M65.2M
Total assets9.71M13.5M31.3M40.8M79.4M54.2M28.5M68.6M121.4M124.9M
Accounts payable890.0K1.54M1.22M614.0K578.0K657.0K1.51M616.0K494.0K563.0K
Current liabilities2.21M2.43M3.26M1.22M1.54M1.36M2.29M1.56M1.44M2.04M
Long-term debt1.01M
Total debt1.50M1.81M1.85M297.0K534.0K596.0K817.0K331.0K1.01M
Total liabilities3.38M3.93M4.88M1.27M1.84M1.74M2.82M1.67M16.0M22.6M
Shareholders' equity6.33M9.52M26.4M39.6M77.5M52.5M25.7M66.9M105.4M102.3M
Shares outstanding13.8M10.2M10.2M8.14M8.14M70.4M35.1M29.9M24.3M23.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-8.19M-16.5M-14.7M-21.4M-12.7M-9.83M-1.56M-8.29M-6.90M-14.7M
Capital spending-12.0K-8.00K-118.0K-74.0K-52.0K-240.0K-145.0K-28.0K-40.0K-51.0K
Free cash flow-8.20M-16.5M-14.8M-21.5M-12.8M-10.1M-1.71M-8.32M-6.94M-14.7M
Cash from investing-12.0K-8.00K-118.0K-74.0K-52.0K-240.0K-145.0K1.37M-40.0K3.00K
Cash from financing5.37M03.99M-27.0K38.5M35.7M6.42M8.89M4.08M9.02M
Share buybacks35.8M6.64M7.91M711.0K9.02M
Change in cash-2.83M-16.5M-10.8M-21.5M25.7M25.6M4.72M1.98M-2.86M-5.64M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
8-K · Current reportSep 9, 2026Current reportSEC
3 · Initial statement of ownershipAug 21, 2026Insider tradeSEC
8-K · Current reportAug 18, 2026Management or board changeSEC
8-K · Current reportAug 17, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
SCHEDULE 13D · Big-stake noticeAug 7, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 7, 2026Big-stake noticeSEC
4 · Change in ownershipAug 6, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipAug 5, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Material contractSEC
8-K · Current reportJul 17, 2026Meeting outcomeSEC
8-K · Current reportJun 9, 2026Management or board changeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportJun 3, 2026Current reportSEC
DEFA14A · Additional proxy materialMay 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementMay 27, 2026Meeting noticeSEC
8-K · Current reportMay 26, 2026Current reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveMay 4, 2026Other filingsSEC
8-K · Current reportApr 30, 2026Current reportSEC
CORRESP · Letter to the SECApr 29, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 28, 2026Other filingsSEC
S-3 · Registration statementApr 23, 2026Offer documentSEC
8-K · Current reportApr 2, 2026Current reportSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportMar 13, 2026Management or board changeSEC
8-K · Current reportMar 9, 2026Current reportSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
8-K · Current reportFeb 19, 2026Current reportSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
8-K · Current reportJan 15, 2026Management or board changeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
8-K · Current reportDec 18, 2025Current reportSEC
8-K · Current reportDec 1, 2025Current reportSEC
4 · Change in ownershipNov 28, 2025Insider tradeSEC
4 · Change in ownershipNov 25, 2025Insider tradeSEC
8-K · Current reportNov 14, 2025ResultsSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
8-K · Current reportOct 30, 2025Material contractSEC
8-K · Current reportOct 27, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 2, 2025Big-stake noticeSEC
424B3 · ProspectusSep 29, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 26, 2025Other filingsSEC
CORRESP · Letter to the SECSep 25, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 24, 2025Other filingsSEC
S-1 · Registration statementSep 19, 2025Offer documentSEC
8-K · Current reportSep 15, 2025Material contractSEC
424B5 · ProspectusSep 15, 2025Offer documentSEC
8-K · Current reportSep 12, 2025Current reportSEC
8-K · Current reportSep 12, 2025Current reportSEC
424B3 · ProspectusSep 12, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 28, 2025Other filingsSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
CORRESP · Letter to the SECAug 13, 2025Other filingsSEC
8-K · Current reportAug 5, 2025Current reportSEC
UPLOAD · Letter from the SECJul 30, 2025Other filingsSEC
8-K · Current reportJul 10, 2025Current reportSEC
8-K · Current reportJul 1, 2025Meeting outcomeSEC
8-K · Current reportJun 18, 2025Current reportSEC
8-K · Current reportJun 5, 2025Current reportSEC
8-K · Current reportMay 29, 2025Current reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialMay 5, 2025Meeting noticeSEC
DEF 14A · Proxy statementMay 5, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 24, 2025Current reportSEC
8-K · Current reportApr 23, 2025Current reportSEC
8-K · Current reportApr 8, 2025Management or board changeSEC
8-K · Current reportApr 1, 2025Current reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportJan 8, 2025Current reportSEC
8-K · Current reportDec 31, 2024Current reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportOct 31, 2024Current reportSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
4 · Change in ownershipOct 11, 2024Insider tradeSEC
8-K · Current reportOct 10, 2024Management or board changeSEC
8-K · Current reportAug 20, 2024Current reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportJul 18, 2024Current reportSEC
8-K · Current reportJun 28, 2024Meeting outcomeSEC
8-K · Current reportJun 20, 2024Current reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
DEF 14A · Proxy statementMay 7, 2024Meeting noticeSEC
8-K · Current reportMay 1, 2024Current reportSEC
PRE 14A · Preliminary proxy statementApr 26, 2024Meeting noticeSEC
10-K/A · Annual report, amendedApr 17, 2024Annual reportSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
8-K · Current reportMar 19, 2024Current reportSEC
8-K · Current reportMar 1, 2024Current reportSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportJan 4, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 2, 2024Big-stake noticeSEC
8-K · Current reportDec 21, 2023Current reportSEC
8-K · Current reportDec 6, 2023Current reportSEC
8-K · Current reportDec 4, 2023Current reportSEC
8-K · Current reportNov 29, 2023Current reportSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
8-K · Current reportOct 31, 2023Current reportSEC
8-K · Current reportAug 16, 2023ResultsSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
4 · Change in ownershipJul 20, 2023Insider tradeSEC
8-K · Current reportJun 15, 2023Current reportSEC
424B5 · ProspectusJun 15, 2023Offer documentSEC
8-K · Current reportJun 12, 2023Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 30, 2023Other filingsSEC
CORRESP · Letter to the SECMay 24, 2023Other filingsSEC
S-3/A · Registration statement, amendedMay 24, 2023Offer documentSEC
UPLOAD · Letter from the SECMay 19, 2023Other filingsSEC
10-Q · Quarterly reportMay 15, 2023Quarterly reportSEC
8-K · Current reportMay 15, 2023ResultsSEC
S-3 · Registration statementMay 12, 2023Offer documentSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
3 · Initial statement of ownershipApr 27, 2023Insider tradeSEC
8-K · Current reportApr 24, 2023Management or board changeSEC
SC 13D/A · Big-stake notice, amendedApr 14, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeApr 12, 2023Big-stake noticeSEC
8-K · Current reportApr 10, 2023Material contractSEC
4 · Change in ownershipApr 6, 2023Insider tradeSEC
8-K · Current reportApr 4, 2023Current reportSEC
10-K · Annual reportMar 29, 2023Annual reportSEC
8-K · Current reportMar 15, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC
8-K · Current reportJan 9, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2022Quarterly reportSEC
8-K · Current reportOct 26, 2022Current reportSEC
8-K · Current reportOct 3, 2022Current reportSEC
8-K · Current reportSep 12, 2022Current reportSEC
10-Q · Quarterly reportAug 15, 2022Quarterly reportSEC
8-K · Current reportAug 15, 2022ResultsSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
4 · Change in ownershipAug 3, 2022Insider tradeSEC
8-K · Current reportJul 29, 2022Management or board changeSEC
8-K · Current reportMay 20, 2022Meeting outcomeSEC
8-K · Current reportMay 19, 2022Current reportSEC
10-Q · Quarterly reportMay 11, 2022Quarterly reportSEC
8-K · Current reportMay 11, 2022ResultsSEC
DEF 14A · Proxy statementApr 11, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 1, 2022Meeting noticeSEC
10-K · Annual reportMar 23, 2022Annual reportSEC
8-K · Current reportMar 23, 2022ResultsSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 3, 2022Big-stake noticeSEC
8-K · Current reportDec 22, 2021Current reportSEC
8-K · Current reportNov 19, 2021Current reportSEC
10-Q · Quarterly reportNov 15, 2021Quarterly reportSEC
8-K · Current reportNov 15, 2021ResultsSEC
8-K · Current reportSep 14, 2021Current reportSEC
4 · Change in ownershipAug 23, 2021Insider tradeSEC
10-Q · Quarterly reportAug 16, 2021Quarterly reportSEC
8-K · Current reportJul 20, 2021Management or board changeSEC
4 · Change in ownershipJul 20, 2021Insider tradeSEC
4 · Change in ownershipJul 20, 2021Insider tradeSEC
4 · Change in ownershipJul 20, 2021Insider tradeSEC

This page holds 200 of 674 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cocrystal Pharma, Inc.’s releases · as of Nov 16, 2026

Common shares
19,264,893
Fully diluted
19,264,893

Fully diluted

LineSharesAs of
Common shares19,264,893Nov 16, 2026

Warrants and options

Lot
Warrants · US$1.24 · expire about Jan 2028
Warrants · US$1.50 · expire about Sep 2027

Share count over time

CountShares
Nov 16, 202619,264,893

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard440K2.3%US$506KSep 30, 2026
Renaissance Technologies175K0.91%US$201KSep 30, 2026
Two Sigma142K0.74%US$164KSep 30, 2026
Geode Capital124K0.65%US$143KSep 30, 2026
BlackRock73,7460.38%US$84,808Sep 30, 2026
Citadel42,6690.22%US$49,069Sep 30, 2026
Neuberger Berman Group LLC31,8860.17%US$36,669Sep 30, 2026
State Street20,5430.11%US$23,624Sep 30, 2026
Parallel Advisors, LLC12,5690.07%US$14,454Sep 30, 2026
Northern Trust11,9210.06%US$13,709Sep 30, 2026
All 25 holders
HolderSharesOf the companyValueAs of
XTX Topco Ltd11,1760.06%US$12,852Sep 30, 2026
Tower Research Capital LLC (TRC)5,4570.03%US$6,276Sep 30, 2026
Wells Fargo5,4170.03%US$6,230Sep 30, 2026
Nuveen1,909<0.01%US$2,138Sep 30, 2026
Morgan Stanley913<0.01%US$1,050Sep 30, 2026
Northwestern Mutual Wealth Management Co817<0.01%US$940Sep 30, 2026
Clean Yield Group418<0.01%US$481Sep 30, 2026
UBS177<0.01%US$204Sep 30, 2026
Nvwm, LLC84<0.01%US$97Sep 30, 2026
SBI Securities Co., Ltd.33<0.01%US$38Sep 30, 2026
JPMorgan27<0.01%US$30Sep 30, 2026
IFP Advisors, Inc13<0.01%US$15Sep 30, 2026
RBC9<0.01%Sep 30, 2026
Citigroup Inc1<0.01%US$1Sep 30, 2026
Fidelity00.00%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund187K0.97%US$197KJun 30, 2026
Vanguard Extended Market Index Fund171K0.89%US$180KJun 30, 2026
Fidelity Extended Market Index Fund49,8070.26%US$55,784May 31, 2026
Fidelity Series Total Market Index Fund9,6290.05%US$10,784May 31, 2026
Fidelity Total Market Index Fund8,5260.04%US$9,549May 31, 2026
Fidelity Nasdaq Composite Index Fund6,1220.03%US$6,857May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Frost Phillip Md Et Al
Director, 10% owner
Buy10,000USD 0.98US$9,800Aug 5, 2026
Frost Phillip Md Et Al
Director, 10% owner
Buy75,000USD 0.94US$70,500Aug 3, 2026

Big stakes

StakeStakeSharesDateFiling
OPKO HEALTH, INC.29.60%5.69MNov 4, 2026Schedule 13D
Phillip Frost, M.D.13.90%2.78MAug 3, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Steve Rubin
Other companies: Entera Bio Ltd. (Director · Since at least Feb 1, 2026); Red Violet, Inc. (Director · Since at least Mar 26, 2018); Niagen Bioscience, Inc. (Director · Since at least Mar 27, 2017); OPKO Health, Inc. (Executive VP-Administration, Director · Since at least Feb 9, 2007); VBI Vaccines Inc. (Director · Dec 31, 2016 – Jun 14, 2018 · Past); Fluent, Inc. (Director · Jan 11, 2010 – Apr 13, 2017 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Castle Brands Inc (Director · Jan 21, 2009 – Oct 8, 2019 · Past); Non-Invasive Monitoring Systems, Inc. (Director · Oct 30, 2008 – Feb 28, 2012 · Past); BioCardia, Inc. (Interim CEO and Interim CFO, Director · Sep 19, 2008 – Aug 11, 2016 · Past); Asensus Surgical Inc (Director · Sep 4, 2007 – Apr 23, 2013 · Past); Dreams Inc (Director · Jun 25, 2007 – Jun 19, 2009 · Past)
Director · Since at least Mar 17, 2014
James Sapirstein
Other companies: INmune Bio Inc. (Director · Since at least Sep 8, 2026); ZyVersa Therapeutics, Inc. (Director · Since at least Jan 5, 2023); Onconetix, Inc. (Director · Feb 23, 2022 – Sep 26, 2024 · Past); Blue Water Acquisition Corp (Director · Dec 15, 2020 – Dec 15, 2020 · Past); Marizyme, Inc. (Interim CEO, Director · Sep 10, 2020 – Mar 5, 2021 · Past); GridAI Technologies Corp. (Chairman and CEO, Director · Oct 8, 2019 – Jul 2, 2024 · Past); Lunai Bioworks Inc. (Director · Mar 6, 2018 – Jun 25, 2024 · Past); Hepion Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jan 3, 2018 – Jan 3, 2018 · Past); RespireRx Pharmaceuticals Inc (Director · Dec 9, 2017 – Dec 9, 2017 · Past)
Chief Executive Officer · Since at least Jun 3, 2026
Richard C Pfenniger Jr
Other companies: Fluent, Inc. (Director · Since at least Oct 6, 2022); GeneDx Holdings Corp. (Director · Since at least Apr 29, 2022); OPKO Health, Inc. (Director · Since at least Jan 24, 2008); BioCardia, Inc. (Director · Oct 24, 2016 – Dec 31, 2020 · Past); Wright Investors' Service Holdings, Inc. (Director · Mar 31, 2015 – Oct 22, 2018 · Past); Asensus Surgical Inc (Director · Aug 24, 2007 – Aug 22, 2024 · Past); Continucare Corp (CEO and President, Director · Mar 24, 2006 – Oct 4, 2011 · Past); Ivax Corp (Director · Jan 26, 2006 – Jan 26, 2006 · Past); GP Strategies Corporation (Director · Feb 2, 2005 – Oct 14, 2021 · Past)
Director · Since at least May 27, 2021
Fred Hassan
Other companies: Recursion Pharmaceuticals, Inc. (Director · Since Oct 31, 2026); EyePoint, Inc. (Director · Since at least Sep 3, 2024); BridgeBio Pharma, Inc. (Director · Since at least Aug 17, 2021); Precigen, Inc. (Director · Since at least Jun 30, 2016); Prometheus Biosciences Inc (Director · May 14, 2021 – Jun 16, 2023 · Past); Time Warner Inc (Director · Jun 1, 2016 – Jun 14, 2018 · Past); Amgen Inc. (Director · Jul 28, 2015 – May 5, 2020 · Past)
Director · Since at least Apr 20, 2023
Jane Hsiao
Other companies: OPKO Health, Inc. (Vice Chairman and Chief Technical Officer · Since at least Feb 9, 2007); Sorrento Therapeutics, Inc. (Director · Jan 25, 2010 – Feb 6, 2012 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Non-Invasive Monitoring Systems, Inc. (Interim CEO, Director · Oct 30, 2008 – Dec 21, 2018 · Past); Asensus Surgical Inc (Director · Aug 24, 2007 – Jun 30, 2021 · Past); Protalix BioTherapeutics, Inc. (de) (Director · Dec 31, 2006 – Jan 31, 2007 · Past); Ivax Corp (Vice Chairman and CTO, Director · Jan 26, 2006 – Jan 26, 2006 · Past)
Director · Mar 17, 2014 – Sep 21, 2018 · Past
Carol Brosgart
Other companies: Galmed Pharmaceuticals Ltd. (Director · Since at least Mar 18, 2026); Mirum Pharmaceuticals, Inc. (Director · Jun 4, 2021 – Jun 2, 2022 · Past); Lunai Bioworks Inc. (Director · Dec 27, 2019 – Jun 25, 2024 · Past); Tobira Therapeutics Inc (Director · Jul 9, 2015 – Nov 1, 2016 · Past)
Director · Since at least Aug 12, 2026
Fred Hassan
Other companies: Recursion Pharmaceuticals, Inc. (Chair of the Board · Since at least Nov 2, 2026); EyePoint, Inc. (Board Member · Since at least Nov 7, 2024)
Director · Since at least Oct 30, 2025
James J. Martin
Other companies: PetVivo Holdings Inc (Director · Mar 12, 2021 – May 24, 2021 · Past); SAB Biotherapeutics, Inc. (Director · Jan 11, 2021 – Jan 11, 2021 · Past)
Chief Financial Officer · Since at least Feb 23, 2017
Roger Kornberg
Other companies: Xenetic Biosciences, Inc. (Non-Executive Director · Since at least Nov 1, 2016); Big Digital Energy, Inc. (Director · Jun 11, 2013 – Jun 11, 2013 · Past)
Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board · Since at least Mar 17, 2014
Walt Addison Linscott
Other companies: Indaptus Therapeutics, Inc. (Chief Operating Officer · Since at least Jul 23, 2021); Intec Pharma Ltd (Chief Business Officer · Jan 1, 2019 – Sep 16, 2020 · Past)
GENERAL COUNSEL AND SECRETARY · Jul 21, 2015 – Jul 21, 2015 · Past
All 19 people
PersonSeat
Anthony J Japour
Other companies: OPKO Health, Inc. (Director · Jan 6, 2020 – Mar 12, 2020 · Past)
Director · Since at least Apr 4, 2019
Douglas L Mayers
Other companies: Idenix Pharmaceuticals Inc (EVP and Chief Medical Officer · Mar 29, 2007 – Aug 5, 2014 · Past)
CHIEF MEDICAL OFFICER · Oct 1, 2015 – Oct 1, 2015 · Past
Phillip Frost
Other companies: OPKO Health, Inc. (CEO & Chairman, Director · Since at least May 10, 2022)
Director · Since at least Jul 25, 2022
Raymond F Schinazi
Other companies: Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2022 · Past)
Director · Nov 25, 2014 – Sep 21, 2018 · Past
Richard C. Pfenniger
Other companies: OPKO Health, Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Oct 30, 2025
Steve Rubin
Other companies: OPKO Health, Inc. (Executive Vice President, Administration and Director · Since at least Feb 4, 2026)
Vice Chairman · Since at least Nov 4, 2026
David S BlockDirector · Nov 25, 2014 – Sep 21, 2018 · Past
Sam LeePresident and Co-CEO · Since at least Oct 9, 2024
Sam LeePresident and Chief Scientific Officer · Since at least Sep 9, 2026

Open People

Log in to ask 6ix AI your own questions about Cocrystal Pharma, Inc.